CY1109493T1 - Παραγωγα οξαζολιου ως παραγοντες η3 υποδοχεα ισταμινης, παρασκευη και θεραπευτικες χρησεις - Google Patents

Παραγωγα οξαζολιου ως παραγοντες η3 υποδοχεα ισταμινης, παρασκευη και θεραπευτικες χρησεις

Info

Publication number
CY1109493T1
CY1109493T1 CY20091100831T CY091100831T CY1109493T1 CY 1109493 T1 CY1109493 T1 CY 1109493T1 CY 20091100831 T CY20091100831 T CY 20091100831T CY 091100831 T CY091100831 T CY 091100831T CY 1109493 T1 CY1109493 T1 CY 1109493T1
Authority
CY
Cyprus
Prior art keywords
nitrogen
formula
ring
compounds
independently
Prior art date
Application number
CY20091100831T
Other languages
English (en)
Inventor
Lisa Selsam Beavers
Serge Louis Boulet
Terry Patrick Finn
Robert Alan Gadski
William Joseph Hornback
Cynthia Darshini Jesudason
Richard Todd Pickard
Freddie Craig Stevens
Grant Matthews Vaught
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1109493T1 publication Critical patent/CY1109493T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Στην παρούσα εφεύρεση περιγράφονται νέες ενώσεις αρυλο οξαζολίου του Τύπου I (I), ή φαρμακευτικώς αποδεκτά άλατα αυτών, οι οποίες έχουν δραστικότητα ανταγωνιστή ή αντίστροφου αγωνιστή του Η3 υποδοχέα ισταμίνης, καθώς και μέθοδοι για την παρασκευή και χρησιμοποίηση τέτοιων ενώσεων. Σε μια άλλη ενσωμάτωση, στην εφεύρεση περιγράφονται φαρμακευτικές συνθέσεις περιέχουσες ενώσεις του Τύπου I καθώς και μέθοδοι χρησιμοποίησης αυτών των συνθέσεων για τη θεραπεία της παχυσαρκίας, γνωστικών ελλειμμάτων, της ναρκοληψίας, και άλλων νόσων που σχετίζονται με τον Η3 υποδοχέα ισταμίνης. Ο Τύπος I (I) ή ένα φαρμακευτικώς αποδεκτό άλας αυτού, όπου: το m ανεξαρτήτως είναι σε κάθε περίσταση 1, 2 ή 3, το Ζ ανεξαρτήτως παριστάνει άνθρακα (υποκατεστημένο με υδρογόνο ή τους προαιρετικούς υποκατάστατες που δεικνύονται εδώ) ή άζωτο, υπό τον όρο ότι όταν το Ζ είναι άζωτο τότε το R6 δεν συνδέεται στο Ζ∙ τα R1 και R2 ανεξαρτήτως είναι -(C1-C7) αλκύλιο (προαιρετικά υποκατεστημένο με ένα έως τρία αλογόνα), ή τα R1 και R2 και το άζωτο στο οποίο συνδέονται σχηματίζουν έναν αζετιδινυλο δακτύλιο, έναν πυρρολιδινυλο δακτύλιο, ή έναν πιπεριδινυλο δακτύλιο, όπου περαιτέρω ο ούτως σχηματισθείς αζετιδινυλο, πυρρολιδινυλο, ή πιπεριδινυλο δακτύλιος μπορεί προαιρετικά να υποκατασταθεί μία έως τρεις φορές με R5∙ το R6 ανεξαρτήτως είναι σε κάθε περίσταση, -Η, -αλογόνο, ή -CH3.
CY20091100831T 2004-07-26 2009-08-06 Παραγωγα οξαζολιου ως παραγοντες η3 υποδοχεα ισταμινης, παρασκευη και θεραπευτικες χρησεις CY1109493T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59119104P 2004-07-26 2004-07-26
EP05773290A EP1786790B1 (en) 2004-07-26 2005-07-14 Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses

Publications (1)

Publication Number Publication Date
CY1109493T1 true CY1109493T1 (el) 2014-08-13

Family

ID=35134220

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100831T CY1109493T1 (el) 2004-07-26 2009-08-06 Παραγωγα οξαζολιου ως παραγοντες η3 υποδοχεα ισταμινης, παρασκευη και θεραπευτικες χρησεις

Country Status (17)

Country Link
US (1) US7666871B2 (el)
EP (1) EP1786790B1 (el)
JP (1) JP4982367B2 (el)
CN (1) CN1989115B (el)
AT (1) ATE432926T1 (el)
AU (1) AU2005275183B2 (el)
BR (1) BRPI0513777A (el)
CA (1) CA2575081C (el)
CY (1) CY1109493T1 (el)
DE (1) DE602005014786D1 (el)
DK (1) DK1786790T3 (el)
ES (1) ES2325865T3 (el)
MX (1) MX2007001029A (el)
PL (1) PL1786790T3 (el)
PT (1) PT1786790E (el)
SI (1) SI1786790T1 (el)
WO (1) WO2006019833A1 (el)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008301B2 (en) * 2004-04-01 2011-08-30 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
WO2006089076A2 (en) 2005-02-18 2006-08-24 Neurogen Corporation Thiazole amides, imidazole amides and related analogues
US7790720B2 (en) * 2005-03-31 2010-09-07 Ucb Pharma, S.A. Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses
ES2483992T3 (es) 2005-11-15 2014-08-08 Otsuka Pharmaceutical Co., Ltd. Compuesto oxazol y composición farmacéutica
MX2008011791A (es) 2006-03-15 2008-09-25 Wyeth Corp Azaciclilaminas-n-sustituidas como antagonistas de histamina-3.
EP2024327A1 (de) * 2006-05-19 2009-02-18 Basf Se Benzoylsubstituierte alanine
AU2007254232A1 (en) 2006-05-19 2007-11-29 Wyeth N-benzoyl-and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PE20081152A1 (es) 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3
US7803825B2 (en) 2007-07-16 2010-09-28 Wyeth Llc Aminoalkylazole derivatives as histamine-3 antagonists
WO2009126782A1 (en) * 2008-04-11 2009-10-15 High Point Pharmaceuticals, Llc Histamine h3 receptor ligands
US8383829B2 (en) * 2008-04-15 2013-02-26 Konica Minolta Holdings, Inc. Electrochromic compound, electrode, and display element
SA110310332B1 (ar) 2009-05-01 2013-12-10 Astrazeneca Ab مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل )
EP2590969B1 (en) 2010-07-06 2014-10-15 AstraZeneca AB Therapeutic agents 976
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
AU2014208964B2 (en) 2013-01-23 2016-09-01 Astrazeneca Ab Chemical compounds
WO2016097071A1 (en) * 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Estrogen receptor modulators and uses thereof
US10011594B2 (en) 2015-06-03 2018-07-03 Bristol-Myers Squibb Company 4-hydroxy-3-(heteroaryl)pyridine-2-one APJ agonists
ES2899906T3 (es) 2015-07-06 2022-03-15 Alkermes Inc Inhibidores bicíclicos de histona desacetilasa
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
WO2018132533A1 (en) 2017-01-11 2018-07-19 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
CA3071861A1 (en) 2017-08-07 2019-02-14 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3819037A1 (de) * 1988-06-04 1989-12-14 Hoechst Ag 2,4-disubstituierte oxazol-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als therapiemittel gegen krankheiten, die durch rhinoviren verursacht werden
WO1995009159A1 (en) * 1993-09-28 1995-04-06 Otsuka Pharmaceutical Company, Limited Quinoxaline derivative as antidiabetic agent
AU3957600A (en) * 1999-04-26 2000-11-10 Boehringer Ingelheim International Gmbh Piperidyl-imidazole derivatives, their preparations and therapeutic uses
JP2004532834A (ja) 2001-03-23 2004-10-28 イーライ・リリー・アンド・カンパニー ヒスタミンh3受容体アンタゴニストである非イミダゾール系アリールアルキルアミン化合物、その製造および治療的使用
DE60316116T2 (de) 2002-02-01 2008-05-29 Novo Nordisk A/S Amide von aminoalkylsubstituierten azetidinen, pyrrolidinen, piperidinen und azepanen
DE10259244A1 (de) * 2002-12-17 2004-07-01 Merck Patent Gmbh N-(Indolethyl-)cycloamin-Verbindungen
US7332508B2 (en) * 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
US7259262B2 (en) * 2003-10-24 2007-08-21 Hoffmann-La Roche Inc. Arylazole derivatives, their manufacture and use as pharmaceutical agents

Also Published As

Publication number Publication date
CN1989115B (zh) 2012-03-21
WO2006019833A1 (en) 2006-02-23
DK1786790T3 (da) 2009-07-20
CA2575081A1 (en) 2006-02-23
CN1989115A (zh) 2007-06-27
US20070197604A1 (en) 2007-08-23
AU2005275183A1 (en) 2006-02-23
EP1786790B1 (en) 2009-06-03
ES2325865T3 (es) 2009-09-22
JP2008507579A (ja) 2008-03-13
DE602005014786D1 (de) 2009-07-16
BRPI0513777A (pt) 2008-05-13
PL1786790T3 (pl) 2009-10-30
MX2007001029A (es) 2007-04-12
EP1786790A1 (en) 2007-05-23
AU2005275183B2 (en) 2011-03-17
SI1786790T1 (sl) 2009-10-31
JP4982367B2 (ja) 2012-07-25
US7666871B2 (en) 2010-02-23
ATE432926T1 (de) 2009-06-15
PT1786790E (pt) 2009-08-18
CA2575081C (en) 2013-05-07

Similar Documents

Publication Publication Date Title
CY1109493T1 (el) Παραγωγα οξαζολιου ως παραγοντες η3 υποδοχεα ισταμινης, παρασκευη και θεραπευτικες χρησεις
DK1735278T3 (da) Histamin H3-receptormidler, fremstilling og terapeutiske anvendelser
RS51137B (sr) Derivat benzimidazola i njegova upotreba kao antagonista receptora aii
NO20064065L (no) Diaminopyrimidiner som P2X3 og P2X2/3 antagonister
AR035548A1 (es) Compuestos organicos
DE602006009773D1 (de) Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen
TWI262917B (en) 2-Furancarboxylic hydrazides and pharmaceutical compositions containing the same
AR036597A1 (es) Derivados de 1h-imidazol que tienen actividad agonista de cb1, agonista parcial de cb1 o antagonista de cb1
ATE446962T1 (de) Thiazolopyridinon-derivate als mch- rezeptorantagonisten
JP2006524225A5 (el)
PE20060079A1 (es) DERIVADOS DE PIRIDILO COMO ANTAGONISTAS DEL RECEPTOR mGlus5
AR062299A1 (es) Derivados de bencimidazol
CY1114112T1 (el) Νεα αρυλαμιδια υποκατεστημενα με πυραζολιο
EA200970705A1 (ru) Новые фармацевтические композиции
MXPA05007115A (es) Nuevos agonistas inversos del receptor cb 1.
EA200970704A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНТАГОНИСТЫ NK1 РЕЦЕПТОРА И БЛОКАТОРЫ Na КАНАЛОВ
PE20060273A1 (es) Derivados de tetrahidroisoquinolilsulfonamidas como moduladores del receptor h3
CY1109694T1 (el) Παραγωγα πυρρολιδινης ως ανταγωνιστες υποδοχεα η3 ισταμινης
CY1110785T1 (el) Ρυθμιστες δραστικοτητας υποδοχεων χημειοκινης, κρυσταλλικες μορφες και μεθοδος
PE20071224A1 (es) Derivados de aminometilpiridina como antagonistas de los receptores cannabinoides 1 (cb1)
RU2010115337A (ru) Трициклические гетероциклические производные
JP2010513489A5 (el)
CY1110453T1 (el) Αναστολεις υποδοχεα η3 ισταμινης, παρασκευη και θεραπευτικες χρησεις
EA200401077A1 (ru) 2-оксазоламины и их применение в качестве антагонистов рецептора 5-ht2b
DE602005015866D1 (de) Azetidin-derivate als ccr-3-rezeptor-antagonisten